Freeline_Logo_Red_RGB.jpg
Freeline Publishes Preclinical Proof-of-Concept Data for FLT190, its AAV Gene Therapy Candidate for Fabry Disease, in the Nature Journal Gene Therapy
19 janv. 2023 08h01 HE | Freeline Therapeutics Holdings plc
Data show increased enzyme activity and reduction of harmful substrate, an established biomarker of efficacy in Fabry disease, in key tissues and organs FLT190 currently being investigated in...
Freeline_Logo_Red_RGB.jpg
Freeline Announces Updated Development Plan and Timelines for FLT190 for People with Fabry Disease
24 mars 2022 07h00 HE | Freeline Therapeutics
Company to progress to second dose cohort in the MARVEL-1 study immediately, with first patient dosing expected in mid-2022 LONDON, March 24, 2022 (GLOBE NEWSWIRE) -- Freeline...
Freeline_Logo_Red_RGB.jpg
Freeline Presents on Its Fabry and Gaucher Disease AAV-Based Gene Therapies at the 18th Annual WORLDSymposium™
08 févr. 2022 07h00 HE | Freeline Therapeutics
FLT190 well-tolerated with promising early efficacy in Fabry disease including sustained α-Gal A expression up to two years GALILEO-1, a first-in-human, open-label, international, multicenter Phase...